Safety and Efficacy of <scp>PTH</scp> 1‐34 and 1‐84 Therapy in Chronic Hypoparathyroidism: A Meta‐Analysis of Prospective Trials

Hypoparathyroidism is the only endocrine deficiency for which hormone replacement therapy is not the standard of care. Although conventional treatments may control hypocalcaemia, other complications such as hyperphosphatemia, kidney stones, peripheral calcifications, and bone disease remain unmet needs. This meta-analysis (PROSPERO registration number CRD42019126881) aims to evaluate and compare the efficacy and safety of PTH